Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D
1. CEO Bourla cites tariff uncertainty affecting U.S. investments. 2. Pfizer expects $150 million costs due to existing tariffs. 3. Investments in R&D depend on tariff negotiations certainty. 4. Global minimum tax impacts attractiveness of U.S. manufacturing. 5. Pfizer maintains full-year outlook amid trade policy uncertainties.